Application of Lefamulin in the treatment of Mycobacterium avium complex infection
Through the combination of Lefamulin and other antibiotics, the mechanism of binding to bacterial ribosomes is used to solve the problem of resistance to anti-tuberculosis drugs by Mycobacterium avians, effective inhibition and treatment of Mycobacterium avians, and broadening its application field.
Patent Information
- Application Number
- CN202410570686.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-09
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-05-09
AI Technical Summary
There are currently no treatment for non-tuberculous mycobacterium (NTM) infections, especially Mycobacterium avians, which are highly resistant to anti-tuberculosis drugs, poor treatment effects, and lack effective standard treatment options.
Lefamulin is used in combination with other antibiotics or drugs to inhibit the activity and infection of Mycobacterium avian by binding to the 23S rRNA domain of the bacterial 50S ribosome, providing a combination of drugs to prevent and treat diseases caused by Mycobacterium avians.
Lefamulin has significant antibacterial activity against Mycobacterium avians, with a minimum antibacterial concentration (MIC) of 0.5μg/mL, and the MIC of clinical isolates can reach 0.03125μg/mL, which broadens the application field for the treatment of NTM infection and provides New method.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, and in particular to application of a semi-synthetic pleuromutilin drug in resisting Mycobacterium avium infection. Background Art
[0002] Non-tuberculous mycobacteria (NTM) refer to mycobacteria other than Mycobacterium tuberculosis complex (MTC) and Mycobacterium leprae. They are Gram-positive, acid-fast, aerobic rods that are widely found in natural environments such as soil, water, and dust. Most of them are saprophytic fungi and can be divided into fast-growing Mycobacterium abscessum complex (MAB), Mycobacterium chelonae, Mycobacterium fortuitum, and Mycobacterium smegmatis; slow-growing Mycobacterium avium complex (MAC), Mycobacterium kansasii, Mycobacterium gordonii, Mycobacterium marinum, etc. (Li Xiangfang, Ding Shoupeng, Gao Jinghua, et al. Research progress on the pathogenic mechanism of non-tuberculous mycobacteria [J]. Chinese Journal of Pathogenic Biology, 2022, 17(03): 352-355.). At present, more than 200 species of non-tuberculous mycobacteria have been isolated, which are conditional pathogens. In recent years, with the continuous improvement and popularization of bacterial isolation technology, the changes in the infectious flora of immunocompromised hosts and other reasons, the occurrence of NTM infection and related diseases has shown an upward trend. It has been reported that the proportion of NTM isolates in culture-positive specimens in my country increased from 4.3% in 1979 to 22.9% in 2010. Among them, the clinical relevance of Mycobacterium avium is relatively high in patients with NTM infection, which is 70-80%. At the same time, Mycobacterium avium is also a non-tuberculous mycobacterium with a high isolation rate in my country, with an isolation rate of up to 9.5%. Mycobacterium avium (M.avium) was first isolated from a chicken with pulmonary cavitation in 1890, and human cases of M.avium infection were not reported until 1930. M. avium is a slow-growing mycobacterium that can resist the phagocytic action of host macrophages and can infect multiple organs in the human body, causing a variety of diseases such as lung disease, lymphadenopathy, skin and soft tissue disease, bone disease, and disseminated NTM disease (DALEY CL, IACCARINO JM, LANGE C, et al. Treatment of non-tuberculous mycobacterial pulmonary disease: an official ATS / ERS / ESCMID / lDSA clinical practice guideline [J]. Clin Infect Dis, 2020, 71(4): 905-913.).
[0003] At the same time, Mycobacterium avium is highly resistant to anti-tuberculosis drugs, and has varying degrees of resistance to common anti-tuberculosis drugs such as rifampicin, streptomycin, ethambutol, and capreomycin. The resistance to ethambutol can reach 94.3%, and the resistance rate to rifampicin and moxifloxacin is as high as 50%. Most strains are resistant to multiple anti-tuberculosis drugs at the same time. Currently, there is no specific drug for the treatment of NTM lung disease, and most NTM are resistant to anti-tuberculosis drugs, and the treatment effect is poor. The official guidelines for the treatment of non-tuberculous mycobacterium pulmonary disease currently recommend that the standard treatment for MAC pulmonary disease is based on macrolide drugs (clarithromycin or azithromycin), combined with rifampicin (or rifabutin), ethambutol and amikacin. Although this regimen can delay the progression of the disease, meta-analysis shows that its cure rate is very low, only 60% to 69% (NASIRI MJ, EBRAHIMI G, AREFZADEH S, et al. Antibiotic therapy success rate in pulmonary Mycobacterium avium complex. A systematic review and meta-analysis [J]. Expert Rev Anti Infect Ther, 2020, 18 (3): 263-273.). And its drug resistance is high, resulting in poor prognosis for patients. Therefore, it is urgent to find highly effective anti-MAC drugs outside the standard treatment regimen.
[0004] Lefamulin was developed by Nabriva Therapeutics and approved by the FDA in August 2019 for the treatment of community-acquired bacterial pneumonia (CABP) in adults. In my country, Lefamulin, developed by the Shanghai Branch of Sumitomo Pharma (Suzhou) Co., Ltd., was also approved by the National Medical Products Administration on November 17, 2023 for the treatment of community-acquired bacterial pneumonia in adults. The antibacterial mechanism of Lefamulin is similar to that of other pleuromutilin derivatives. It inhibits bacterial protein synthesis by selectively binding to the A site and P site of the peptidyl transferase center in the central part of the V domain of the 23S rRNA domain of the bacterial 50S ribosome. Its unique mechanism of action causes the molecule to bind tightly to the target site, hindering the correct positioning of t RNA, thereby inhibiting peptide bond formation and peptide chain elongation. However, if the peptide chain has been extended, lefamulin will become ineffective (Xiao Qianwen. Lefamulin (Xenleta) [J]. Chinese Journal of Medicinal Chemistry, 2020, 30 (7): 451-452; Mercuro N j, Veve M P. Clinical utility of lefamulin: lf not now, when [J]. Curr Infect Dis Rep, 2020, 22 (9): 135-140).The antimicrobial spectrum of lefamulin covers the most relevant pathogens causing CABP, including (1) Gram-positive bacteria: Streptococcus pneumoniae (including multidrug-resistant isolates causing lower respiratory tract infections) and Staphylococcus aureus (methicillin-susceptible, methicillin-resistant, and vancomycin-resistant isolates); (2) Gram-negative bacteria: Haemophilus influenzae (including β-lactamase-producing Haemophilus influenzae), Legionella pneumophila, and Moraxella catarrhalis; (3) atypical respiratory pathogens: Mycoplasma pneumoniae (including macrolide-susceptible and -resistant strains) and Chlamydia pneumoniae (Mendes RE, Farrell CV, Flamm RK, et al. in vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States[J]. Antimicrob Agents Chemother,2016,60(7):4407-4411;Waites KB,Crabb DM,Dufy LB,et al.Invitro activities of lefamulin and other antimicrobial agents againstmacrolide.susceptible and macrolde-resistant mycoplasma pneumonlae from theunied States,Europe,and china[J].Antimicrob Agenis Chemother,2017,61(2)e02008-16; Sader HS, Paukner S, lvezic-Schoenfeld 2, et al. Antimicrobial.
[0005] activity of the novel pleuromutilin antibiotic BC-3781againstorganisms responsible for
[0006] communityacquired respiratory tract infections(CARTls)[J].JAntimicrob Chemother,
[0007] 2012,67(5):1170-1175). Currently, there is no report on the inhibition of Mycobacterium avium by Lefamulin. Summary of the invention
[0008] The present invention was completed based on the discovery that Lefamulin has the effect of inhibiting the activity of Mycobacterium avium.
[0009] In a first aspect, the present invention provides a pharmaceutical composition, comprising Lefamulin and another drug for preventing Mycobacterium avium infection.
[0010] The pharmaceutical composition has at least one of the following effects:
[0011] a) inhibiting the activity of Mycobacterium avium;
[0012] b) Anti-Mycobacterium avium infection;
[0013] c) prevention and / or treatment of diseases caused by Mycobacterium avium.
[0014] Furthermore, the Mycobacterium avium includes a standard strain of Mycobacterium avium, a clinical isolate of Mycobacterium avium, or Mycobacterium avium carried by a patient infected with Mycobacterium avium.
[0015] Furthermore, the lowest concentration of the pharmaceutical composition is no less than the minimum inhibitory concentration (MIC) of Mycobacterium avium that it inhibits.
[0016] Furthermore, the other anti-Mycobacterium avium infection drug includes one or more of antibiotics and other drugs that can help inhibit or kill Mycobacterium avium or provide resistance to patients.
[0017] Furthermore, the antibiotics include one or more of rifampicin, streptomycin, ethambutol, moxifloxacin, clarithromycin and / or amikacin; and the other drugs include one or more of vitamins, amino acids, proteins and / or minerals.
[0018] Furthermore, one or more pharmaceutically acceptable carriers may be added to the pharmaceutical composition.
[0019] Furthermore, the pharmaceutical composition can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral solution or pharmaceutical excipients; the above various dosage forms of drugs can be prepared according to conventional methods in the pharmaceutical field.
[0020] Furthermore, the pharmaceutical composition can be introduced into the body such as muscle, intradermal, subcutaneous, intravenous or mucosal tissue by injection, penetration, absorption, physical or chemical mediation; or introduced into the body after being mixed or encapsulated with other substances.
[0021] In a second aspect, the present invention provides a use of Lefamulin in preparing a product for inhibiting Mycobacterium avium.
[0022] Furthermore, the Mycobacterium avium includes a standard strain of Mycobacterium avium, a clinical isolate of Mycobacterium avium, or Mycobacterium avium carried by a patient infected with Mycobacterium avium.
[0023] Furthermore, the Mycobacterium avium inhibition product comprises one or more of a drug and / or an antibacterial agent.
[0024] In a third aspect, the present invention provides a use of Lefamulin in the preparation of a medicament for preventing and / or treating a disease caused by Mycobacterium avium infection.
[0025] Lefamulin works in the following ways:
[0026] 1) Lefamulin inhibits the activity of Mycobacterium avium;
[0027] 2) Lefamulin kills Mycobacterium avium.
[0028] Furthermore, the Mycobacterium avium includes a standard strain of Mycobacterium avium, a clinical isolate of Mycobacterium avium, or Mycobacterium avium carried by a patient infected with Mycobacterium avium.
[0029] Furthermore, the antibiotics include one or more of rifampicin, streptomycin, ethambutol, moxifloxacin, clarithromycin and / or amikacin; and the other drugs include one or more of vitamins, amino acids, proteins or minerals.
[0030] Furthermore, one or more pharmaceutically acceptable carriers may be added to the pharmaceutical composition.
[0031] Furthermore, the pharmaceutical composition can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral solution or pharmaceutical excipients; the above various dosage forms of drugs can be prepared according to conventional methods in the pharmaceutical field.
[0032] Furthermore, the pharmaceutical composition can be introduced into the body such as muscle, intradermal, subcutaneous, intravenous or mucosal tissue by injection, penetration, absorption, physical or chemical mediation; or introduced into the body after being mixed or encapsulated with other substances.
[0033] Beneficial Effects
[0034] Lefamulin in the present invention has good antibacterial activity against standard strains and clinical isolates of Mycobacterium avium, and the MIC of the standard strain of Mycobacterium avium can reach 0.5 μg / mL, and the MIC of the clinical isolate of Mycobacterium avium can reach 0.03125 μg / mL at best;
[0035] The invention broadens the application field of Lefamulin and provides a new method for treating Mycobacterium avium infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 The MIC concentration distribution of Lefamulin against clinically isolated Mycobacterium avium. DETAILED DESCRIPTION
[0037] The following examples are provided for a better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the following examples are purchased from conventional biochemical reagent stores unless otherwise specified. The quantitative tests in the following examples were repeated three times, and the results were averaged.
[0038] Explanation of terms
[0039] Meta-analysis: It refers to a statistical method that quantitatively integrates the results reported by multiple independent studies on the same clinical problem. It has the advantages of improving statistical power and the accuracy of effect value estimation. In addition, it can explain the heterogeneity between different research results. It is a very important statistical analysis method for systematic reviews.
[0040] Community acquired bacterial pneumonia (CABP) refers to infectious lung parenchymal inflammation contracted outside the hospital, including pneumonia caused by pathogens with a clear incubation period after admission to the hospital. The main pathogen is Streptococcus pneumoniae, in addition, it also includes Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus.
[0041] Pleuromutilin: a natural product with antibacterial activity discovered in the 1950s. It is a class of diterpenoid compounds with a tricyclic skeleton produced by submerged culture of the higher fungi basidiomycetes Pleurotus mutilus and Pleurotus passeckerianus.
[0042] Standard strain of Mycobacterium avium: ATCC 25291.
[0043] Lefamulin: purchased from MedchemExpress, product number: HY-16908A, molecular formula: C 28 H 45 NO5S, CAS No. 1350636-82-6. The structural formula is as follows:
[0044]
[0045] Example 1. Detection of the antibacterial activity of Lefamulin against standard strains of Mycobacterium avium
[0046] Preparation method of Mycobacterium avium standard strain suspension: Take the Mycobacterium avium standard strain and inoculate it into neutral Roche medium. After culturing in a 37°C incubator for 3 to 4 weeks, scrape the strain in the logarithmic growth phase on the neutral Roche medium, grind the bacteria and compare the turbidity, then dilute it with Mueller Hinton (MH) medium (containing 5% OADC) for use.
[0047] 1. Add 100 μl Mueller-Hinton (MH) medium (containing 5% OADC) to each well of a 96-well plate;
[0048] 2. After completing step 1, take a 96-well plate, add 100 μl of the drug solution to be tested (prepared with DMSO) with a concentration of 128 μg / mL to the first column, aspirate 100 μl after mixing, add to the second column, dilute to the 11th column in sequence, take 100 μl and discard, the last column does not contain drugs, which is the positive control well. Set up 3 replicates for each concentration.
[0049] 3. After completing step 2, take a 96-well plate and add 100 μl of Mycobacterium avium standard strain suspension to each well, so that the final volume in each well is 200 μl and the final concentration of the bacterial suspension is 4×10 5 CFU / mL; the final drug concentration in each well is shown in Table 1.
[0050] 4. After completing step 3, place the 96-well plate in a 37°C incubator and culture for 9 days.
[0051] 5. After completing step 4, take a 96-well plate, add 20 μl ALamar blue and 50 μl 5% Tween 80 to each well, and culture in a 37°C incubator for 24 hours.
[0052] 6. After completing step 5, take the 96-well plate, read the minimum inhibitory concentration (MIC) and calculate the inhibition rate.
[0053] Table 1
[0054]
[0055] Minimum inhibitory concentration (MIC) reading method: Minimum inhibitory concentration (MIC) is the drug concentration that can inhibit 90% of bacterial colony growth. The minimum drug concentration that inhibits >90% of the production of reduced Alamar blue by fluorescence detection (Ex / Em, 530nm / 600nm).
[0056] Inhibition rate % = 100% - (fluorescence value of the detection well - background fluorescence value) / (fluorescence value of the growth control well - background fluorescence value) × 100%.
[0057] The background fluorescence value is the fluorescence value of the negative control, and the fluorescence value of the growth control well is the fluorescence value of the positive control.
[0058] The negative control was a culture medium without drugs and bacterial solution, and the positive control was a culture medium containing bacteria without drugs.
[0059] The results showed that the MIC of Lefamulin against the standard strain of Mycobacterium avium was 0.5 μg / mL.
[0060] Example 2: Detection of the antibacterial activity of Lefamulin against clinically isolated Mycobacterium avium strains
[0061] Clinical isolates: 23 strains isolated and cultured from sputum specimens of patients infected with Mycobacterium avium were identified as Mycobacterium avium by sequencing of 16SrRNA, hsp65, rpoB, and 16-23S rRNA intergenic region.
[0062] Drug to be tested: Lefamulin
[0063] According to the method in Example 1, the antibacterial activity of the drug to be tested against 23 clinically isolated Mycobacterium avium strains was detected.
[0064] The MIC results are shown in Table 2. The statistical results of MIC concentration distribution are shown in Tables 3 and Figure 1 shown.
[0065] Table 2
[0066]
[0067]
[0068] Table 3
[0069]
[0070] The results showed that Lefamulin had good antibacterial activity against Mycobacterium avium, with the best MIC reaching 0.03125 μg / mL, and it is expected to be used in the clinical treatment of Mycobacterium avium infections.
Claims
1. An application of Lefamulin in the preparation of a product for inhibiting Mycobacterium avium.
2. The use according to claim 1, wherein the product comprises one or more of a drug and / or an antibacterial agent.
3. Use of Lefamulin in the preparation of a drug for preventing and / or treating diseases caused by Mycobacterium avium infection, Lefamulin works in the following ways: 1) Lefamulin inhibits the activity of Mycobacterium avium; 2) Lefamulin kills Mycobacterium avium.
4. The use according to claim 3, wherein the Mycobacterium avium comprises a standard strain of Mycobacterium avium, a clinical isolate of Mycobacterium avium, or Mycobacterium avium carried by a patient infected with Mycobacterium avium.
Citation Information
Patent Citations
Application of sutezolid (PNU-100480) to mycobacterium avium composite flora infection
CN111096969A
Application of fidaxomicin in preparation of product for inhibiting activity of mycobacterium avium
CN112190589A
Methods for preventing or treating a disease or condition associated with mycobacterium avium subspecies paratuberculosis
US20130101615A1
Antimicrobial cartridges and processes for antimicrobial susceptibility testing
WO2018144918A1
Novel compound having therapeutic activity against mycobacterium avium complex infection, and method for producing same
WO2019044941A1
